Ipsen Deal History & Licensing Activity
Ipsen is a large pharma headquartered in France. Over the past three years, Ipsen has been involved in 1 licensing and acquisition transaction, with a primary focus on Small Molecules (1 deal).
Deals (12mo)
1
Active Trials
15
Top Modality
Small Molecules
Focus Area
Oncology
Ipsen Pipeline Focus
Therapeutic areas and modalities where Ipsen is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Ipsen Strategic Signals
Key indicators of Ipsen's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
Strategic Profile
Acquisition Appetite
Strategic Priorities
See How Your Asset Matches Ipsen's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Oncology assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Ipsen Licensing & Deal Activity
Ipsen is a large pharma company based in France that has been actively engaged in licensing transactions across the biopharma landscape. With 1 deal over the past three years, Ipsen ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Ipsen include Oncology (1 deal and trial). In terms of modality, Ipsen has shown particular interest in small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Ipsen and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Ipsen's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.